clinical trial · NCT05766839
Patiromer for Treatment of Hyperkalaemia in Children Under 12 Years of Age
Vifor Pharma, Inc.·phase2·recruiting·n = 32
HyperkalemiaPatiromer
brief summary
A study to evaluate the pharmacodynamic effects, safety, and tolerability of patiromer in children under 12 years of age with hyperkalaemia.
started
Apr 6, 2025
primary completion
Dec 1, 2029
completion
Dec 1, 2030
last updated
Mar 13, 2026
official title
A 2-Part, Open-Label, Phase 2, Multiple Dose Study to Evaluate the Pharmacodynamic Effects, Safety, and Tolerability of Patiromer in Children Under 12 Years of Age With Hyperkalaemia (EMERALD2)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol